New York, September 11, 2024 - PRISM MarketView - The clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, OS Therapies (OSTX) today announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate (tADC) platform. The first therapeutic candidate leverages a folate receptor alpha targeting small molecule combined with hexa-exatecan payloads (OST-tADC-FRA-H) linked together with the Company’s proprietary silicone linker technology, SiLinker™. The data from this illustrated strong antitumor activity in the KB and IGROV-1 mouse models of ovarian cancer. Taken together, the data provide compelling preclinical proof of concept that the Company’s SiLinker™ platform can be used to develop new therapeutic tADC-based drug candidates that can improve the safety and/or efficacy of ADC combinations currently on the market or in development, in addition to creating new intellectual property for competitive and life cycle management purposes.
OST-tADC technology is designed around OS Therapies’ proprietary next-generation tunable Antibody Drug Conjugate (tADC) platform which utilizes pH-sensitive silicon-based linkers, trademarked as SiLinkers™, which can release multiple therapeutic agents selectively within the tumor and tumor microenvironment. This allows for lower pH levels than the rest of the body with the objective to maximize the therapeutic effects while minimizing damage to healthy cells.
“We are very pleased with the results of this proof-of-concept data demonstrating that our tADC silicone linker SiLinker technology is able to safely deliver multiple payloads to the tumor without demonstrating side effects of payload loss in animal models of ovarian cancer. With the ability to link multiple payloads, including with different therapeutic agent combinations, we are potentially revolutionizing the way antibody drug conjugates will be constructed in the future.”
Colin Goddard, PhD, tADC Founder and member of the OS Therapies ADC Advisory Board
According to Grandview Research, in 2023 the global Antibody Drug Conjugate market size was estimated at $11.29Bn and is expected to grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030 equating to approximately $20.9Bn. Furthermore, Grandview also estimates the global ovarian cancer drugs market size to be $3.37Bn in 2022 with the expectation for it to reach $5.6Bn with a CAGR of 6.6% from 2023 to 2030.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities